| Literature DB >> 35402388 |
Gianluca Utzeri1, Pedro M C Matias1, Dina Murtinho1, Artur J M Valente1.
Abstract
Nanosponges are solid cross-linked polymeric nano-sized porous structures. This broad concept involves, among others, metal organic frameworks and hydrogels. The focus of this manuscript is on cyclodextrin-based nanosponges. Cyclodextrins are cyclic oligomers of glucose derived from starch. The combined external hydrophilicity with the internal hydrophobic surface constitute a unique "microenvironment", that confers cyclodextrins the peculiar ability to form inclusion host‒guest complexes with many hydrophobic substances. These complexes may impart beneficial modifications of the properties of guest molecules such as solubility enhancement and stabilization of labile guests. These properties complemented with the possibility of using different crosslinkers and high polymeric surface, make these sponges highly suitable for a large range of applications. Despite that, in the last 2 decades, cyclodextrin-based nanosponges have been developed for pharmaceutical and biomedical applications, taking advantage of the nontoxicity of cyclodextrins towards humans. This paper provides a critical and timely compilation of the contributions involving cyclodextrins nanosponges for those areas, but also paves the way for other important applications, including water and soil remediation and catalysis.Entities:
Keywords: crosslinked polymers; cyclodextrins; multipurpose structures; nanosponges; responsive materials; supramolecular interactions
Year: 2022 PMID: 35402388 PMCID: PMC8987506 DOI: 10.3389/fchem.2022.859406
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
FIGURE 1Number of papers that includes the keywords “cyclodextrin” and “nanosponge” cited by the Web of Science till 23.12.2021 (accessed at 12:41 GMT).
FIGURE 2Schematic representation of CDNSs main applications and their advantages.
Crosslinking agents used in the preparation of different categories of CDNSs.
| CDNSs classes | Crosslinkers |
|---|---|
| Carbonate | Carbonyls: diphenyl carbonate (DPC); 1,1′-carbonyl diimidazole (CDI); dimethyl carbonate (DMC) and triphosgene |
| Carbamate | Diisocyanates: 1,6-hexamethylene diisocyanate (HDI); methylene diphenyl diisocyanate (MDI) |
| Ester | Dianhydrides: pyromellitic dianhydride (PMA); ethylenediaminetetraacetic acid dianhydride (EDTA) |
| Carboxylic acids: citric acid (CA) | |
| Ether | Epoxides: epichlorohydrin; 1,4-butanediol diglycidylether (BDE) |
| Polyamidoamine | 2,2′-bis(acrylamido)acetic acid and its polyamidoamine derivates (PAA) formed by reaction with amines (such as 2-methylpiperazine) |
| Polyamine | Polyamines: 1,6-hexanediamine (am6), 1,8-octanediamine, 1,12-dodecanediamine (am12) |
| Other linkers | Dichloromethane |
FIGURE 3Synthesis of CDNSs through the reaction between β-cyclodextrin and a crosslinker, being carbonyls, diisocyanates, dianhydrides, carboxylic acids and epoxides the most common.
Comparative properties of different types of CDNSs.
| Nanosponge | Method | Structure | Mean size/nm | PDI | ζ-Potential/mV | SBET/m2 g−1 | Pore diameter/nm | Pore volume/cm3g−1 | |
|---|---|---|---|---|---|---|---|---|---|
| βCD:DPC | Melt | C/A | <664 | <0.45 | − (3–22) | 9.7 (1:2) |
|
| |
| βCD:DPC | Solvent | A | 135–500 | <0.43 | ± (12–35) | 2.2 (1:2) | 13.3 (1:2) | 0.0075 (1:2) | |
| βCD:DPC 1:4 | MW | C | 153 ± 8 | 0.11 ± 0.01 | 28 ± 2 | <2.0 | — | — | |
| βCD:CDI 1:4 | Solvent | A | 473 ± 1 | 0.24 ± 0.06 | −(39 ± 1) | 10.9 | 4.86 | 0.013 | |
| Interfacial | — | 173 ± 1 | 0.22 ± 0.03 | −(33 ± 1) | — | — | — | ||
| CD:HDI | Solvent | A | 420×103 | — | — | 1.7–3 | — | 0 | |
| CD:TDI | Solvent | A | 367 ± 2 | 0.25 ± 0.02 | −(26 ± 2) | 1.7–3 | — | 0 | |
| αCD:MDI 1:10 | Solvent | A | 100–200 | — | — | 11.9 | 35.9 | 0.11 | |
| βCD:PMA | 1:4 | Solvent | A | 605 ± 18 | 0.31 ± 0.03 | −(61 ± 2) | 1.21 | 120.3 | 0.04 |
| 1:6 | 264 ± 16 | 0.26 ± 0.01 | −(60 ± 2) | 0.573 | 484.8 | 0.07 | |||
| 1:8 | 477 ± 23 | 0.72 ± 0.06 | −(60 ± 3) | 0.393 | 299.9 | 0.03 | |||
| GSH-NS: βCD:PMA/2-HEDS | Solvent | A | 203 ± 14 | 0.20 ± 0.01 | −(32 ± 3) | — | — | — | |
| βCD: Epiclon | 1:2 | Solvent | A | 300 ± 10 | 0.27 | −(24 ± 2) | 0.4 | 105 | - |
| 1:4 | 206 ± 9 | 0.20 | −(27 ± 2) | 6.0 | 22 | ||||
| 1:8 | 140 ± 6 | 0.19 | −(37 ± 2) | 9.3 | 16 | ||||
| βCD:CA | NADES | A | <20×103 | — | 5–18 | 9.0 | — | — | |
| βCD:CA 1:8 | Solvent | — | 800 | — | −(29 ± 11) | 1.30 | — | — | |
| Extrusion | — | — | −(26 ± 7) | 0.93 | — | — | |||
| βCD:EPI | Solvent | A | 167 ± 8 (1:8) | 0.58 (1:8) | −(37 ± 2) (1:8) | 10.9 (1:10) | 4.86 (1:10) | 0.014 (1:10) | |
| CD:am6
| Solvent | A | 446 ± 30 | 0.38 ± 0.05 | 41 ± 6 | 21.8 | 24.3 | 0.13 | |
| CD:am12
| Solvent | A | 438 ± 38 | 0.43 ± 0.03 | 54 ± 7 | 17.9 | 7.5 | 0.03 | |
| PAA:NS | Solvent | — | 410–502 | 0.10–0.12 | −(32–35) | — | — | — | |
| βCD:acrylic acid | Chain-growth | A | 275 ± 29 | 0.28 | −(41 ± 5) | — | — | — | |
A: amorphous; C: crystalline.
Some recent examples (2020–2021) of first generation CDNSs applications in pharmaceuticals.
| Nanosponge | Drug | Application | Main results |
|---|---|---|---|
| α-, βCD:CDI | Oxyresveratrol | Anticancer drug delivery | Strong cell viability inhibition for HT-29 and HCT-116 cancer cell lines |
| βCD:PMA; βCD:DPC | Irbesartan | Solubility enhancement | PMA crosslinker enhanced the drug solubility (81.86 folds) and drug release to a greater extent than DPC crosslinker; encapsulation efficiency up to 38% |
| βCD:PMA | Insulin | Protein delivery | Loading capability 14%; encapsulation efficiency >90%; |
| HPβCD + βCD:CDI | Artemether Lumefantrine | Drug delivery | Entrapment efficiencies of 70.6% for artemether and 88.3% for lumefantrine; |
| βCD:DPC | Clobetasol propionate | Topical delivery | Drug release 86.25%; Appreciable anti-psoriatic activity and alleviated severity of side effects |
| βCD:DPC | Sesamol | Photostability enhancement | Encapsulation efficiency 90.66%; Enhancement of stability, while retaining antioxidant and anti-tyrosinase potential |
| βCD:DPC | Febuxostat | Oral bioavailability enhancement | ≥30% release at first hour followed by controlled release (≥75%) at 6 h |
| βCD:DMC | Paracetamol + aceclofenac + caffeine | Solubility/combination therapy enhancement |
|
| βCD:CDI | Econazole nitrate | Topical delivery | Entrapment efficiency 70.13%; nanogel was able to impede the fungal growth both |
| βCD:CDI | Sulfamethoxazole | Solubility enhancement | Improved solubility up to 30-fold |
| βCD:PMA | ICOS-Fc | Cancer therapy |
|
| βCD:CDI | flutamide | Anticancer drug delivery | Increased dissolution rate, sustained release and considerable uptake into PC3 cell line was observed |
| βCD:CDI | Bortezomib | Anticancer drug delivery | Uptake of 93.9% in 3 h against MCF-7 cell line; Higher IC50 in comparison with the plain drug |
| βCD:PMA | Doxorubicin | Cancer therapy | Higher accumulation in the tumor and neoplastic cells; Reduced cardiotoxicity |
| βCD:DPC | Thyme essential oil | Solubility and volatility reduction enhancement | Increased antibacterial activity; Aqueous solubility enhanced 15-folds; Minimum inhibitory concentration decreased up to 29.4 fold after encapsulation |
| βCD:DPC | Limonene essential oil | Solubility and volatility reduction enhancement | Enhanced solubility and thermal stability; Higher antibacterial activity; Minimum inhibitory decreased after encapsulation |
| βCD:DMC | curcumin + caffeine | Topical delivery | 69.72% |
ICOS-Fc: soluble recombinant form of inducible T-cell costimulatory.
Recap of the main results of heavy metals removal by different nanosponge formulations.
| Nanosponge | Pore size/(nm) | Surface area/(m2 g−1) | Heavy metal | qm/(mg g−1) | Removal efficiency (RE%) | References |
|---|---|---|---|---|---|---|
| βCD:CA (1:8) | n.a | n.a | n.a./20–70 (high conc.); 80 (Cu(II), Zn(II) at low conc.); 80, 60 (Cu(II), Zn(II) in artificial sea water) | n.a | 20–70 (high conc.); 80 (Cu(II), Zn(II) at low conc.); 80, 60 (Cu(II), Zn(II) in artificial sea water) |
|
| βCD:EPI (1:6) | n.a | n.a | Cu(II)/23/≥ 90 in water; Cd(II)/43/≥ 90 in water |
| ||
| βCD:EDTA (1:17) | n.a | n.a | Cu(II)/79/95 in a model textile effluent | |||
| Cd(II)/124/95 in a model textile effluent | ||||||
| βCD:PMA (1:8) | n.a | n.a | n.a./20–70 (high conc.); 80 (Cu(II), Zn(II) at low conc.); 80, 60 (Cu(II), Zn(II) in artificial sea water) | n.a | 20–70 (high conc.); 80 (Cu(II), Zn(II) at low conc.); 80, 60 (Cu(II), Zn(II) in artificial sea water) |
|
| β-MCD:VI (1:100) | 0.02 | 27.5 | Pb(II)/18/n.a |
| ||
| Cu(II)/55/n.a | ||||||
| Cd(II)/65/n.a | ||||||
| Zn(II)/50/n.a | ||||||
| Ni(II)/25/n.a | ||||||
| Co(II)/20/n.a | ||||||
| βCD:TFP (1:3) | 3 | 271 | Pb(II)/196/70 |
| ||
| Cu(II)/164/77 | ||||||
| Cd(II)/136/83 | ||||||
| βCD:TDI (1:10) | 1.6 | 2.4 | As(V)/n.a./≈10 |
| ||
| βBZMCD:TDI (1:10) | 77.6 | 1.3 | As(V)/n.a./≈95 | |||
| βCD:TPC:TA (1:4) | <10 | 2.3 | Pb(II)/136/≈90 |
|
Molar ratio values in mol/mol.
Selected examples of nanosponges application for dye removal.
| Nanosponge | Pore size/(nm) | Surface area/(m2 g−1) | Dye/qm (mg g−1)/RE (%) | References |
|---|---|---|---|---|
| βCD:EPI (1:135) | n.a | n.a | DirectBlue 78/24/n.a |
|
| αCD:EPI (1:115) | n.a | n.a | DirectRed83:1/32/93 |
|
| HP-αCD:EPI | n.a | n.a | DirectRed83:1/23/75 | |
| βCD:EPI (1:6) | n.a | n.a | Methylene blue/50/≥ 90; Safranin/6/≥ 90; Crystal violet/42/≥ 90 |
|
| βCD:EDTA (1:17) | n.a | n.a | Methylene blue/84/n.a.; Safranin/60/n.a.; Crystal violet/114/n.a | |
| MCD:MPP (1:1) | 2–10 | n.a | Rhodamine B/10/n.a.; Congo Red |
|
| β-MCD:VI (1:100) | 0.02 | 28 | Rhodamine B/175/60; Congo red/712/100 |
|
| β-BCD:PD | no porous | 22 | Methyl orange/285/77; Congo red/288/80; Rhodamine B/n.a./n.a.; Methylene blue/n.a./n.a |
|
| βCD‒P5 (1:1) | 4 | 479 | Methylene blue/135/78 |
|
| βCD:FPS (1:2) | 5–6 | n.a | 2‒naphthol/n.a./>80 |
|
| 2‒naphthol/n.a./>99 (flow through) | ||||
| βCD:CMP(H) | 1–10 | 1,099 | nitrobenzene/325/80 |
|
| 2‒nitrophenol/310/75 | ||||
| 2‒nitroaniline/290/70 | ||||
| 4‒nitroaniline/275/65 | ||||
| 2‒chloroaniline/300/75 |
MPP [2,2′‒azobis (2‒methylpropionitrile)].
Values of molar ratio in mol/mol.
The main types of CDNSs applied for the adsorption of pesticides.
| Nanosponge | Pore size/(nm) | Surface area/(m2 g−1) | Pesticide/ | References |
|---|---|---|---|---|
| αCD:EPI (1:115) | n.a | n.a | Atrazine/≈0.07/≈60 |
|
| βCD:EPI (1:115) | n.a | n.a | Atrazine/≈0.07/≈60 |
|
| Multiplex | 5 | 1–4 | Atrazine/10/30 |
|
| Benalaxyl/23/65 | ||||
| Bromacil/11/25 | ||||
| Butachlor 115/85; butene fipronil/6/98 | ||||
| fenamiphos/21/60 | ||||
| fipronil/8/85 | ||||
| fomesafen/25/25 | ||||
| pretilachlor/83/55 | ||||
| simazine/1/28 | ||||
| βCD:EPI/KMnO4 | 4 | 1 | Atrazine/n.a./17 |
|
| Benalaxyl/n.a./70 | ||||
| Bromacil/n.a./19 | ||||
| Butachlor/n.a./80 | ||||
| Fenamiphos/n.a./58 | ||||
| Fipronil/n.a./48 | ||||
| Flufiprole/n.a./80 | ||||
| Pretilachlor/n.a./40 | ||||
| βCD:am6 (1:20) | 24 | 22 | Imidacloprid/68/97 |
|
| BZM-βCD:TDI (1:10) | 78 | 1 | 2‒chlorophenol/n.a./25 |
|
| 4‒chloro‒3‒methylphenol/n.a./90 | ||||
| 4‒nitrophenol/n.a./80 | ||||
| 2,4,6‒trichlorophenol/n.a./85 | ||||
| 2‒nitrophenol/n.a./70 | ||||
| 2,4‒dinitrophenol/n.a./85 | ||||
| 2,4‒dichlorophenol/n.a./70 | ||||
| βCD:TTI3% (1:2) | n.a | 34 | 2,4‒dichlorophenol/145/68 |
|
| βCD:TFP (1:3) | 2–4 | 263 | 2,4‒dichlorophenol/14/85 |
|
| 1‒naphtyl amine/13/92 | ||||
| Metolachlor/26/92 | ||||
| βCD:TFP:THTS (1:1:2) | 2–25 | 231 | 2,4‒dichlorophenol/≈500/≈90 |
|
| βCD:DPC (1:4) | 2 | 3 | 4‒chlorophenoxyacetic acid/1/91 |
|
| 2,3,4,6‒tetrachlorophenol/1/78 | ||||
| αCD | non-porous | n.a | Carbendazim/0.3/90 (after 5 h) |
|
Molar ratio values in mol/mol.
Nanosponges developed for drug removal (2015–2019).
| Nanosponge | Pore size/(nm) | Surface area/(m2 g−1) | Drugs/ | References |
|---|---|---|---|---|
| αCD:CA | n.a | — | Progesterone/n.a./95 |
|
| βCD:CHI (1:1) | n.a | n.a | Testosterone/n.a./98–100; epitestosterone/n.a./98–100; androsterone/n.a./98–100; etiocholanolone/n.a./98–100; 5α‒androstane‒3α,17β‒diol/n.a./98–100; 5β‒androstane‒3α,17β‒diol/n.a./98–100 |
|
| βCD:PFP:CTS/EDTA (1:2,900) | 1 | 48 | 6‒bromo‒2‒naphtol/0.30/> 90 |
|
| βCD:TFP:THTS (1:1:2) | 2–25 | 231 | Propranolol hydrochloride/≈100/n.a |
|
| βCD:TFP (1:3) | 2–4 | 21 | ethynyl oestradiol/n.a./≈60; propranolol hydrochloride/n.a./≈90 |
|
| n.a | Chloroxylenol/144/91; Carbamazepine/136/65 |
| ||
| βBCD:CMP | 2–5 | 1,107 | Albendazole/180/96 |
|
| βCD:HDI (1:4) | n.a | n.a | Ibuprofen/86/<70 |
|
Values of molar ratio in mol/mol.